Immunotoxicology Specialty
Section NewsletterO u t g o i n g P re s i d e n t ’s M e s s a g e
Rodney Dietert, PhD

2012 - 2013
Executive Committee
President
Dr. Greg Ladics
Vice President
Dr. Gary Burleson
Vice President-Elect
Dr. Danuta Herzyk
Secretary-Treasurer
Dr. Susan McKarns
Past President
Dr. Rodney Dietert
Senior Councilor
Dr. Jean Pfau
Junior Councilor
Dr. L. Peyton Myers
PostDoc Representative
Dr. Teri Alyn Girtsman
Student Representative
Kinta Serve
The ImTox SS Newsletter is published 3times/year (Summer, Fall, and Winter). If you
would like to share a book review, meeting
report, interesting web site or any other item ofinterest with members of the Specialty
Section, please send it to us by the middle ofthe month preceding the planned publication
date. All comments on, or suggestions for, thenewsletter are welcome.
Communications Committee Co-Chairs
Haley Neff-LaFord, PhD:
hnlaford@seagen.com
Ashwini Phadnis:
phadnisa@msu.edu
Typesetting / desktop publishing provided by
L. Peyton Myers, Ph.D.

July 2012

In my incoming message as President last spring, I
recognized and expressed appreciation for our recent
benchmark celebrations: the recent 25th Anniversary of
our SS and the 50th Anniversary of SOT. The path wehave taken thus far was wonderfully summarized in areview of the history of immunotoxicology by RobertHouse and MaryJane Selgrade published in
Toxicological Sciences. That review detailed theaccomplishments of immunotoxicologists including Dr. Rodney Dietert,
so many of our SS members. It placed a marker and a
PhD
way station in the road that allows us to see our President, ImTox SS
progress to date, even as we must now choose among(2011-2012)multiple paths, multiple possibilities for the way
ahead.
Rather than identifying goals with a strickly 12-month view for the SS and
Executive Committee for 2011-2012, I laid out longer-term priorities that I
believed would help to place us in the forefront of toxicology organizations
and prepare our future generations of immunotoxicologists. The key was
asking the question: what do we want to accomplish by (or even before) our50th SS anniversary?
The four priority goals were: Feeding the Leadership Pipeline, Reaching New
Audiences,
GlobalInterconnectivity,andTraining
FutureImmunotoxicologists.
I want to emphasize that while our SS committees were in place andfunctioning to support progress on these priorities (e.g., the Regional Meeting
Committee which is now the Extending Immunotoxicology -Regional Meeting
Committee) much of what actually happened would not have occurred but for
the grassroots activities of our members. This past year in particular, ourmembers seized openings in many different areas of programming that are
Incoming President’s Message ................................................. pages 3-4
Committee Reports .........................................................................page 5
ImTox SS 2010-2011 Committees ..................................................page 6
Awards ......................................................................................... pages 7-9
Pictures from SOT Meeting March 2012 ............................. pages 10-12
Recent Immunotoxicology Publications ............................... pages 13-16

1

Immunotoxicology Specialty Section

increasing the visibility and impact of immunotoxicology. This programming will pay dividends for our areain future years. It is so important for our SS members to continue to watch for these opportunities to arise evenas they move their individual careers forward.
Here are just a few examples of how our immunotoxicology landscape is shifting.
Feeding the Leadership Pipeline:
The present year our SS had Judy Zelikoff as Secretary of the SOT and Dori Germolec as a Councilor.
The new election brought Norb Kaminski in as the SOT Vice President Elect. On the heels of Michael
Holsapple’s Presidency, we will soon have another SS member as SOT President. Congratulations Norb.
Outside of SOT, several of our members have moved up in corporate and/or institutional positions andresponsibilities further emphasizing the need for earlier career immunotoxicologists to take their place.
Examples are Leigh Ann Burns-Naas’ appointment as Vice President at Gilead Science and Scott Burchielassuming the role as Editor of TAAP. Immunotoxicologists are taking on higher levels of responsibility andoverall impact
Reaching New Audiences - Spearheaded largely through SS members at the NIEHS and/or via the efforts ofour members involved with the EPA, the WHO, HESI, other national institutes, and academic partners, several
events have or will soon occur that are shifting scientific and public perceptions regarding immunotoxicology.


The NIH elevated the priority of inflammation as the root of chronic diseases via a recent educational
program delivered throughout the institutes to all grant panel managers and internal scientists.



The WHO published its monograph titled “Guidance for Immunotoxicity Risk Assessment for Chemicals“that lays out a broader view of immunotoxicology when it comes to risk assessment. These results weresummarized in a CEC at the most recent SOT meeting and will be presented at an upcoming EUTOX
meeting.



HESI established a new initiative around the science of adjuvants and potential risk of autoimmunity.



The EPA found that safety limits can be driven by developmental immunotoxicity for trichloroethylene ina newly released IRIS of TCE document that was just published.

The NIEHS paved the way for a special immunotoxicology program involving our SS members at theannual meeting of the American Association of Immunologists.



The Teratology Society is including a special session on risks for the developing immune system at its
upcoming meeting.



The NIEHS presented a program on environment, inflammatory dysfunction and chronic diseases for it
research and educational partners in the PEHP program.



The publisher, Springer, is set to publish a similarly-themed book along the lines of the NIEHS
programming.

The European Teratology Society presented a session on early-life immunotoxicity and risk of asthma.

Global Interconnectivity:

July 20122

Immunotoxicology Specialty Section

The heart and soul of our global connectivity effort is our programming partnership with the Japanese Societyof Immunotoxicology(JSIT). The past year we were successful in SOT’s Global Initiatives Program and, withthose funds in conjunction with support from the Journal of Immunotoxicology and InformaHealthcare, wewere able to exchange representatives with JSIT for programming in Japan and the U.S. Greg Ladics
presented two lectures at the annual conference of the JSIT and Dr. Reiko Teshima of the Division of Novel
Foods and Immunochemistry, the National Institute of Health Sciences of Japan co-chaired an
immunotoxicology session at our most recent SOT meeting in San Francisco. Continuation, if not expansion,of these types of international joint programming in immunotoxicology will be important for our future global
perspective and impact.
Training Future Immunotoxicologists:
Training future immunotoxicologists is linked with the health of our research and educational programs. Thisin turn relies on funding from both public and private sources. Recent programming at the NIH and otherfederal agencies has increased the visibility of the linkage between immunotoxicology and human health. It is
this increased appreciation of the impact of immunotoxicology among our peers, particularly those on grantand other evaluation panels, that affects our training capabilities. I suspect this will be an area requiring
ongoing attention to ensure we are bringing forward the next generation of immunotoxicologists.
I want to thank the Executive Committee, our Committee Chairs, our volunteer committee members andadditional specialty section members for your support and for the outstanding progress that was made this past
year. It has been a wonderful opportunity and tremendous honor to serve as the 2011-2012 Immunotoxicology
Specialty Section President. Thank you so much for this privilege. I look forward to continued service in therole of Past President on the Executive Committee and to the upcoming year with Greg Ladics as our SS
President. Let’s all work to make SOT in San Antonio the best yet.

Incoming President’s Message
Submitted by: Greg Ladics, Ph.D., President ImTox SS 2012-2013
I bid greetings to all my fellow members of the Immunotoxicology Specialty
Section (ImToxSS). Thinking back, it has been over 23 years since I attended myfirst SOT Meeting and ImToxSS reception in Atlanta, GA. Wow- I guess thismeans I am ‘slowly’ becoming one of those “silverbacks” as affectionately referred
to by Robert House. It has been quite the fun ride through graduate school at
Virginia Commonwealth University/Medical College of Virginia and an ongoing
21 year career at DuPont. So many members of our Specialty Section have helped Dr. Greg Ladics, PhD
President, ImTox SS
shape my career, in particular Al Munson, Kimber White, Tom Kawabata, and(2012-2013)
Scott Loveless. Looking forward, I was pleased to see such a large number ofstudents and postdocs at our ImToxSS reception in San Francisco this year. They represent the future of
Immunotoxicology and our specialty section.
I would like to express thanks to Dr. Rod Dietert for his leadership as ImToxSS President this past year. Rod,sorry you were unable to attend the specialty section meeting in San Francisco. You were dearly missed! I
would also like to thank the executive committee officers, committee chairs and committee members for theirtime and effort in helping our specialty section. Congratulations to our incoming ImToxSS officers Danuta
July 20123

Immunotoxicology Specialty Section

Herzyk (VP-Elect) and Peyton Meyers (Junior Councilor). Additionally, Norb Kaminski Vice-President Electof SOT; Judy Zelikoff, the 2012 Vos Award recipient; Barbara Kaplan the 2012 Young Investigator Awardwinner and all of the student and post doctoral presentation award recipients deserve our congratulations. I
would also like to recognize our specialty section members and Gary Burleson and the Program Committee forcoming up with no less than 20 proposals (5 symposia, 6 workshops, 5 roundtables, 2 informational sessions,and 2 CE courses) for consideration for the 2013 meeting. This should again provide maximum exposure for
the ImToxSS at next years’ meeting in San Antonio. Gary, what’s your secret? Please pass it on to Danuta!
As you may recall, one of the previous goals of our specialty section involved continuing to follow up on the
toxicology study section and immunotoxicology grant review issues. This entailed the formation of an ad hoc
IRG subcommittee of our specialty section. Earlier this year, an expert Working Group met at NIH in
Bethesda to advise the Center for Scientific Review on how to proceed with the review of grant applications in
the fields of Environmental Health and Toxicology. The Working Group agreed on a recommendation toreconstitute the Special Emphasis Panel called Systemic Injury from Environmental Exposure as a chartered
Study Section in the DKUS IRG and to meet for 1 to 3 review cycles, before moving on to request permanent
chartered status. This is indeed good news and may not have come to fruition were it not for members of our
specialty section pushing this issue to the forefront.
In thinking about goals for our specialty section in the coming year, two priorities come to mind. The first(Goal 1) is around improving the financial status of our specialty section. Goal 2 is to continue to explore
ways of getting more visibility for immunotoxicology scientists. One idea is to put a proposal forward for an
SOT Contemporary Concepts in Toxicology (CCT) meeting around immunotoxicology. CCT meetings areone- to two-day focused, open registration, scientific meetings in contemporary and rapidly progressing areasof toxicological sciences. As you may be aware, SOT will underwrite all the liabilities of the CCT meetingwith the expectation that the meeting will at least break even financially. SOT will provide $25,000 in seedfunds. Once the meeting breaks even, there is the opportunity for profit sharing of the additional revenue with
our specialty section which could help with Goal 1.
CCT proposal details are available atwww.toxicology.org/ai/meet. I will be forming small but diverse ad hoc committees to work on both of thesegoals in 2012.
If you are interested in working on one or both, please send me a note at
Gregory.s.ladics@usa.dupont.com.
I look forward to working with our executive and other committees this coming year and to seeing everyone in
San Antonio!
Gregory S. Ladics, Ph.D., DABT, ATS
President, Immunotoxicology Specialty Section
2012-2013

July 20124

Immunotoxicology Specialty Section

Student &Postdoctoral
ReportSubmitted by:
Teri Girtsman, Postdoctoral
Representative

teri.girtsman@mso.umt.edu if you
would like to participate inorganizing ImTox SS events or for
any questions relating to the
ImTox SS.

Hello to all student andpostdoctoral members of the
ImTox SS! I hope you are having
a great spring and are generating
brilliant data!

A plug for postdocs and students
to check out the SOT web site foraward opportunities for students
and postdocs at http://
www.toxicology.org/ISOT/SS/
imtox/deadlines.asp for all of thelatest information related to
ImTox SS.

I would like to welcome Kinta
Serve from Idaho State University
to the ImTox SS executive
committee. Kinta has agreed toserve as the graduate student
representative for the upcoming
term. Please feel free to contact
Kinta servkint@isu.edu or myself

I would like to thank the students
who toughed out the rain to attend
the ImTox SS Postdoc/Student
mixer at Thirsty Bear Brewing
Company during the 51st Annual
Meeting in March at San
Francisco. We had a great time
relaxing and enjoying a cold

July 20125

beverage or two- althoughattendance was limited due to thesoggy weather (got to love San
Francisco!).
As always, I would like to thankyou for this opportunity to serveyou. Please let me know about
any concerns or suggestions you
may have on how the ImTox SS
can best assist you as
immunotoxicology students andpostdoctoral fellows!
I lookforward to hearing from you!
Have a great summer!!
Postdoctoral Representative,
Teri Alyn Girtsman Ph.D.

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section
Committee Lists: 2012-2013
Communications

AwardsProgramCommittee

Committee

Committee

Haley Neff-LaFord (Co-chair)

Jean Pfau (Chair)

Danuta Herzyk (Chair)hnlaford@seagen.com

pfaujean@isu.edu

danuta_herzyk@merck.com

Ashwini Phadnis (Co-chair)

Xiaomia Deng

Joshua Arrington

phadnisa@msu.edu

Teri Girtsman

Tony ArulanandamJamie Dewitt

Vic Johnson

Weimin Chen

Thitirat Ngaotepprutaram

M. Firoze Khan

Vic Johnson

Cheryl Rockwell

Jean Regal

Peer Karmaus

Tom Simones

Cheryl Rockwell

M. Firoze Khan

Narendra Singh

Peyton Myers

Berran Yucesoy

Thitirat Ngaotepprutaram

ImTox Regional
Meeting
Committee
Leigh Ann Burns Naas (Chair)

Narendra Singh

Regulatory
Committee

leighann.burns@pfizer.com

Peter Thomas (Chair)Rodney Dietert

peter.thomas@covance.com

Susan McKarns

Joshua Arrington

Kathy Rodgers

Tony Arulanadam

Lorraine Twerdok

Lorraine Twerdok

Judy Zelikoff

Education

Membership

Committee

Committee

Judy Zelikoff (Chair)

George DeGeorge (Chair)judith.zelikoff@nyumc.org

degeorge@mbresearch.com

Thitirat Ngaotepprutaram

Mitch Cohen

July 2012

6

Jim Weaver
Berran Yucesoy

If you would like to join acommittee, there are still
places on the Regulatory,
Communications, Education
andAwardsC o mmittees. Please contact theI mTox SS Sec retaryTreasurer or the Chairpersonof the committee(s) if you areinterested in joining.

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section Awards
Presented at SOT Annual Meeting, March 2012
San Francisco, CA
Submitted by: Kazuchi Nakamura
It was a really exciting but difficult job to select the award winners because all of submitted papers were excellent. This year’s winners are as follows.
Vos Award Career Achievement in Immunotoxicology

Judith T. Zelikoff, PhD

Best Paper 2011
Narendra P. Singh, Udai P. Singh, Balwan Singh, Robert L. Price, Mitzi Nagarkatti,
Prakash S. Nagarkatti. Activation of Aryl Hydrocarbon Receptor (AhR) Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 Expression and Amelioration of Experimental Colitis. PLoS ONE, 2011, 6(8):1-13
Outstanding Young Investigator Award

Barbara L.F. Kaplan, PhD

HESI Travel AwardDavid J. Blake, PhD

Best Presentation by a Postdoctoral Fellow
David Adenuga, PhD‘Immunological Aspects of an Animal Model of Amodiaquine-Induced Liver Toxicity’Best Presentation by a Student – 1st Place
Ana-Cristina Dragomir“Regulation of Classical and Alternative Macrophage Activation by Galectin-3
Following Acetaminophen Intoxication”
Best Presentation by a Student – 2nd Place
Ashwini S. Phadnis“Suppression of activation and altered BCL-6 regulation by
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in human primary B cells”
CONGRATULATIONS to all the winners! I thankfully learned many new aspects and trends of immunotoxicology studies during the selection. This year most of nominees are from academia. I would like to encourage
submissions from people working for companies next year as well.
Reviewing all of the submissions was done by dedicated works of Berran Yucesoy, Michelle J. Horner, Haitian Lu, Narendra P. Singh (not participating in selecting the Best Paper of the Year Award), Jean C. Pfau
(Junior Councilor.). Please extend your warm gratitude for their contribution.
I have served as a Junior and Senior Councilor of the Immunotoxicology Specialty Section for two years intotal. I appreciate your generous acceptance and tolerance. Especially, I would like to thank Dr. Leigh Ann
Burns-Naas and Dr. Rodney Dietert for their support and patience.
Finally, please let me take this opportunity to wish you all of the very best.

July 20127

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section Awards Winners - 2012

Vos Award - Career Achievement in Immunotoxicology Winner: Judith T. Zelikoff, PhD

Best Paper of the Year Award Winner: Narendra P. Singh,
Udai P. Singh, Balwan Singh, Robert L. Price, Mitzi
Nagarkatti, Prakash S. Nagarkatti. Activation of Aryl
Hydrocarbon Receptor (AhR) Leads to Reciprocal
Epigenetic Regulation of FoxP3 and IL-17 Expression andAmelioration of Experimental Colitis. PLoS ONE, 2011,
6(8):1-13

July 20128

HESI Immunotoxicology
Young Investigator TravelAward Winner: David J.
Blake, PhD

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section Awards Winners - 2012

2nd Place Student Presentation
Award Winner: Ashwini S.
Phadnis

1st Place Student Presentation
Award Winner: Ana-Cristina
DragomirOutstanding Young
Investigator Award Winner:
Barbara L.F. Kaplan, PhD

July 2012

Best Presentation by a
Postdoctoral Trainee Winner:
David Adenuga, PhD

9Immunotoxicology Specialty Section

Immunotoxicology Specialty Section - 2012

July 201210

Immunotoxicology Specialty Section

ImTox Business Meeting - 2012

July 201211

Immunotoxicology Specialty Section

ImTox Business Meeting - 2012

July 201212

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Compiled by Haley Neff-LaFord.
Anytime you have a new fully published or electronically-available article to report, please send it to thecoordinator, Haley Neff-LaFord: hnlaford@seagen.com

Asthma, Allergy, Autoimmunity & Hypersensitivity
Adenuga D, Woolhiser MR, Gollapudi BB and Boverhof DR. Differential gene expression responses
distinguish contact and respiratory sensitizers and nonsensitizing irritants in the local lymph node assay.
Toxicol Sci 126, 413-425, 2012.
Anderson SE, Tapp L, Durgam S, Meade BJ, Jackson LG and Cohen DE. The identification of a sensitizing
component used in the manufacturing of an ink ribbon. J Immunotoxicol 9:193-200, 2012.
Kimber I, Maxwell G, Gilmour N, Dearman RJ, Friedmann PS and Martin SF. Allergic contact dermatitis: acommentary on the relationship between T lymphocytes and skin sensitising potency. Toxicology 291:18-24,
2012.
Patil SD, Patel MR, Patel SR and Surana SJ. Amaranthus spinosus Linn. inhibits mast cell-mediatedanaphylactic reactions. J Immunotoxicology 9:77-84, 2012.
Peiser M, Tralau T, Heidler J, Api AM, Arts JHE, Basketter DA, English J, Diepgen TL, Fuhlbrigge RC,
Gaspari AA, Johansen JD, Karlberg AT, Kimber I, Lepoittevin JP, Liebsch M, Maibach HI, Martin SF, Merk
HF, Platzek T, Rustemeyer T, Schnuch A, Vandebriel RJ, White IR and Luch A. Allergic contact dermatitis:
epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Cell Mol Life Sci 69:763-781,
2012.
Roberts DW, Basketter D, Kimber I, White J, McFadden J and White IR. Sodium metabisulfite as a contact
allergen – an example of a rare chemical mechanism for protein modification. Contact Derm 66:123-127,
2012.
Developmental Immunotoxicology
Hanson ML, Holaskova I, Elliott M, Brundage KM, Schafer R and Barnett JB. Prenatal cadmium exposure
alters postnatal immune cell development and function. Toxicol Appl Pharmacol 261:196-203, 2012.
Holladay SD, Mustafa A and Gogal RM Jr. Prenatal TCDD in mice increases adult autoimmunity. Reprod
Toxicol 92:82-94, 2011.
Mustafa A, Holladay SD, Witonsky S, Kerr R, Reilly C, Zimmerman K, Manari A, Countermarsh S and Gogal
RM Jr. Prenatal TCDD causes persistent modulation of the postnatal immune response, and exacerbates
inflammatory disease, in 36-week-old lupus-like autoimmune SNF1 mice. Birth Defects Res B Dev Reprod
Toxicol 92:82-94, 2011.
Mustafa A, Holladay SD, Witonsky S, Reilly C, Sponenberg DP and Gogal RM Jr. A single mid-gestation
exposure of C57BL/6 mice to TCDD causes permanent postnatal shifts toward an autoreactive immune
phenotype. Toxicology 290:157-169, 2011.
Schaalan MF, Abdelraouf SM, Mohamed WA and Hassanein FS. Correlation between maternal milk andinfant serum levels of chlorinated pesticides (CP) and the impact of elevated CP on bleeding tendency andimmune status in some infants in Egypt. J Immunotoxicol 9:15-24, 2012.
July 201213

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Tonk ECM, Verhoef A, De La Fonteyne LJJ, Waalkens-Berendsen IDH, Wolterbeek APM, Van Loveren H
and Piersma AH. Developmental immunotoxicity in male rats after juvenile exposure to di-n-octyltin
dichloriede (DOTC). Reprod Toxicol 32:341-348, 2011.
Ul Hassan Z, Khan MZ, Khan A, Javed I and Noreen M. In vivo and ex vivo phagocytic potential ofmacrophages from progeny of breeder hens kept on ochratoxin A (OTA)-contaminated diet. J Immunotoxicol
9:64-71, 2012.

Effects: Compounds
Antonini JM, Zeidler-Erdely PC, Young SH, Roberts JR and Erdely A. Systemic immune cell response in rats
after pulmonary exposure to manganese-containing particles collected from welding aerosols. J
Immunotoxicol 9:184-192, 2012.
Dar SA, Das S, Ramachandran VG, Bhattacharya SN, Mustafa MD, Banerjee BD and Verma P. Alterations in
T-lymphocyte sub-set profiles and cytokine secretion by PBMC of systemic lupus erythematosus patients uponin vitro exposure to organochlorine pesticides. J Immunotoxicol 9:85-95, 2012.
Dhir V, Fort M, Mahmood A, Higbee R, Warren W, Narayanan P and Wittman V. A predictive biomimetic
model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J
Immunotoxicol 9:34-42, 2012.
Fair PA, Stavros HC, Mollenhauer MAM, DeWitt JC, Henry N, Kannan K, Yun SH, Bossart GD, Keil DE and
Peden-Adams MM. Immune function in female B6C3F1 mice is modulated by DE-71, a commercial
polybrominated diphenyl ether mixture. J Immunotoxicol 9:96-107, 2012.
Khan S, Vala JA, Nabi SU, Gupta G, Kumar D, Telang AG and Malik JK. Protective effect of curcumin
against arsenic-induced apoptosis in murine splenocytes in vitro. J Immunotoxicol 9:148-159, 2012.
Li B, Niu Y, Liu S, Yu W, Chen J, Wu L, Liu W, Chen S, Yang L and Li Y. A change in CD3γ, CD3δ, CD3ϵ,and CD3ζ gene expression in T-lymphocytes from benzene-exposed and benzene-poisoned workers. J
Immunotoxicol 9:160-167, 2012.
Nakamura R, Inoue K, Fujitani Y, Kiyono M, Hirano S and Takano H. Effects of nanoparticle-rich diesel
exhaust particles on IL-17 production in vitro. J Immunotoxicol 9:72-76, 2012.
Osman A and Van Loveren H. Phosphoproteomic analysis of mouse thymoma cells treated with tributyltinoxide: TBTO affects proliferation and energy sensing pathways. Toxicol Sci 126:84-100, 2012.
Rafferty P, Egenolf D, Brosnan K, Makropoulos D, Jordan J, Meshaw K, Walker M, Volk A and Bugelski P.
Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma andB-cell lymphoma in C3H mice. J Immunotoxicol 9:43-55, 2012.
Rasmussen DL and Pfau JC. Asbestos activates CH12.LX B-lymphocytes via macrophage signaling. J
Immunotoxicol 9:129-140, 2012.
Salazar KD, Copeland CB and Luebke RW. Effects of Libby amphibole asbestos exposure on two models ofarthritis in the Lewis rat. J Toxicol Environ Health A 75:351-365, 2012.
Schaalan MF. Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin
resistance. J Immunotoxicol 9:201-209, 2012.

July 201214

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Ul Hassan Z, Khan MZ, Saleemi MK, Khan A, Javed I and Noreen M. Immunological responses of maleWhite Leghorn chicks kept on ochratoxin A (OTA)-contaminated feed. J Immunotoxicol 9:56-63, 2012.

General Immunotoxicology
Ali SK, Ali HYM and Jubrael JMS. Concentration levels of IL-10 and TNFα cytokines in patients with humanpapilloma virus (HPV) DNA+ and DNA− cervical lesions. J Immunotoxicol 9:168-172, 2012.
Lebrec H, O’Lone R, Freebern W, Komocsar W and Moore P. Survey: Immune function and immunotoxicity
assessment in dogs. J Immunotoxicol 9:1-14, 2012.
Pucca MB, Zoccal KF, Roncolato EC, Bertolini TB, Campos LB, Cologna CT, Faccioli LH, Arantes EC andBarbosa JE. Serrumab: A human monoclonal antibody that counters the biochemical and immunologicaleffects of Tityus serrulatus venom. J Immunotoxicol 9:173-183, 2012.
Shaw FL, Kimber I, Begum R, Cumberbatch M, Dearman RJ and Griffiths CEM. No impairment of
monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis. Clin Exp Dermatol 37:4047, 2011.
Siveen KS and Kuttan G. Effect of Aerva lanata on cell-mediated immune responses and cytotoxic Tlymphocyte generation in normal and tumor-bearing mice. J Immuntoxicol 9:25-33, 2012.
Van Loveren H, Sanz Y and Salminen S. Health Claims in Europe: Probiotics and Prebiotics as Case
Examples. Ann Rev Food Sci Technol 23:1-15, 2012.

Methods
White KL Jr., McLoughlin CE, Auttachoat W and Smith MJ. Validation of the Candida albicans delayed-type
hypersensitivity (DTH) model in the female B6C3F1 mouse for use in immunotoxicological investigations. J
Immunotoxicol 9:141-147, 2012.

Reviews/Workshops/Editorials
Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A,
Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J,
McVey EA, Ouedraogo G, Patelwicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A,
Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J and Hartung T. A roadmap for thedevelopment of alternative (non-animal) methods for systemic toxicity testing. ALTEX 29:3-91, 2012.
Collinge M, Burns-Naas LA, Chellman GJ, Kawabata TT, Komocsar WJ, Piccotti JR, Shenton J and Wierda
D. Developmental immunotoxicity (DIT) testing of pharmaceuticals: Current practices, state of the science,
knowledge gaps, and recommendations. J Immuntotoxicol 9:210-230.
Hrubec TC, Prater MR, Mallela MK, Gogal RM Jr, Guo TL and Holladay SD. Diverse ability of maternal
immune stimulation to reduce birth defects in mice exposed to teratogens: A review. Journal for
Developmental Origins of Health and Disease. Epub Nov. 2011.

July 201215

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Kamperschroer C, Kaur A and Lebrec H. A summary of meeting proceedings for ‘Measuring immune
responses in non-human primates for drug development—Opportunities and challenges for predicting humanefficacy and immunotoxicity.’ J Immunotoxicol 9:108-120, 2012.
Kawabata T, Weaver J, Thomas D, Rowe M, Wang F, Kamperschroer C and Haggerty H. Summary ofroundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans. J
Immuntoxicol 9:121-127, 2012.
Silverstone AE, Rosenbaum PF, Weinstock RS, Bartell SM, Foushee HR, Shelton C and Pavuk M.
Polychlorinated biphenyl (PCB) exposure and diabetes: Results from the Anniston Community Health Survey.
Environ Health Perspect 120:727-732, 2012.

Books/ Book Chapters
Rovida C, Ryan C, Cinelli S, Basketter D, Dearman R and Kimber I. The local lymph node assay. Current
Protocols in Toxicology (Supplement 51), 207:1-14, 2012.

July 201216

Immunotoxicology Specialty Section